[{"NetIncomeLoss_1_Q1_USD":-122967000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":181370000.0,"CommitmentsAndContingencies_0_Q1_USD":null,"InventoryFinishedGoodsNetOfReserves_0_Q1_USD":1806000.0,"InterestPaidNet_1_Q1_USD":0.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":-3121000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":10458000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1_Q1_shares":121000.0,"AssetsCurrent_0_Q1_USD":1099051000.0,"OtherNoncashIncomeExpense_1_Q1_USD":-2345000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_1_Q1_USD":295314000.0,"CostOfGoodsAndServicesSold_1_Q1_USD":5756000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":19393000.0,"ResearchAndDevelopmentInProcess_1_Q1_USD":2248000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q1_USD":17106000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q1_USD":-766000.0,"InventoryWorkInProcessNetOfReserves_0_Q1_USD":13082000.0,"Assets_0_Q1_USD":1456561000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q1_USD":-826000.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":124971000.0,"GeneralAndAdministrativeExpense_1_Q1_USD":31679000.0,"DepreciationAndAmortization_1_Q1_USD":3543000.0,"PreferredStockSharesOutstanding_0_Q1_shares":0.0,"IncreaseDecreaseInOtherAccruedLiabilities_1_Q1_USD":-7345000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_1_Q1_USD":303612000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1_Q1_USD":-20000.0,"OtherNonoperatingIncomeExpense_1_Q1_USD":1412000.0,"AccountsReceivableNetCurrent_0_Q1_USD":29156000.0,"IncomeTaxExpenseBenefit_1_Q1_USD":92000.0,"CommonStockValue_0_Q1_USD":18000.0,"AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0_Q1_USD":96093000.0,"IncreaseDecreaseInEmployeeRelatedLiabilities_1_Q1_USD":8981000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":17856000.0,"ProceedsFromDerivativeInstrumentFinancingActivities_1_Q1_USD":750000.0,"CostsAndExpenses_1_Q1_USD":133039000.0,"IncreaseDecreaseInInventories_1_Q1_USD":1516000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-123793000.0,"IncreaseDecreaseInAccountsPayable_1_Q1_USD":779000.0,"OtherAssetsNoncurrent_0_Q1_USD":1435000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":150164000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":134556000.0,"AdditionalPaidInCapitalCommonStock_0_Q1_USD":3429734000.0,"Cash_0_Q1_USD":7559000.0,"Liabilities_0_Q1_USD":462055000.0,"OtherAssetsCurrent_0_Q1_USD":15771000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":95604000.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.0001,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1_Q1_USD":10.82,"LiabilitiesFairValueAdjustment_1_Q1_USD":-1599000.0,"Goodwill_0_Q1_USD":76501000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-122875000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":23898000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q1_USD":-60000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-77085000.0,"InventoryRawMaterialsNetOfReserves_0_Q1_USD":1920000.0,"ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_1_Q1_USD":5036000.0,"LiabilitiesCurrent_0_Q1_USD":123633000.0,"AccountsPayableCurrent_0_Q1_USD":22434000.0,"NonoperatingIncomeExpense_1_Q1_USD":-13483000.0,"InterestExpense_1_Q1_USD":0.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":150164000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_1_Q1_USD":17106000.0,"StockIssuedDuringPeriodSharesShareBasedCompensation_1_Q1_shares":2199000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":14833000.0,"IncreaseDecreaseInOtherOperatingAssets_1_Q1_USD":-6183000.0,"NumberOfOperatingSegments_1_Q1_segment":1.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":58510000.0,"ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_1_Q1_USD":18800000.0,"CommonStockSharesOutstanding_0_Q1_shares":182290000.0,"IncreaseDecreaseInAccountsReceivable_1_Q1_USD":-9733000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":-48791000.0,"CommonStockSharesAuthorized_0_Q1_shares":300000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":23647000.0,"OperatingIncomeLoss_1_Q1_USD":-109392000.0,"AllowanceForDoubtfulAccountsReceivable_0_Q1_USD":0.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q1_USD":887152000.0,"InventoryNet_0_Q1_USD":16808000.0,"PreferredStockValue_0_Q1_USD":0.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":1456561000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q1_USD":23513000.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.0001,"PreferredStockSharesAuthorized_0_Q1_shares":10000000.0,"DerivativeLiabilitiesNoncurrent_0_Q1_USD":4597000.0,"OperatingLeaseLiabilityCurrent_0_Q1_USD":15768000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1_Q1_USD":1057000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.68,"ProfitLoss_1_Q1_USD":-122967000.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":4130000.0,"StockholdersEquity_0_Q1_USD":994506000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":2876000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-2432125000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":23898000.0,"IncreaseDecreaseInContractWithCustomerLiability_1_Q1_USD":-605000.0,"Ticker":"NKTR","CIK":"906709","name":"NEKTAR THERAPEUTICS","OfficialName":"Nektar Therapeutics  Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"862449342.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210507"}]